Get the Stockscreener App
27.08
0.18%
0.05
After Hours:
27.75
0.67
+2.47%
Mbx Biosciences Inc stock is traded at $27.08, with a volume of 772.64K.
It is up +0.18% in the last 24 hours and up +76.88% over the past month.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
See More
Previous Close:
$27.03
Open:
$26.83
24h Volume:
772.64K
Relative Volume:
0.60
Market Cap:
$1.22B
Revenue:
-
Net Income/Loss:
$-47.20M
P/E Ratio:
-17.30
EPS:
-1.5653
Net Cash Flow:
$-43.65M
1W Performance:
+9.24%
1M Performance:
+76.88%
6M Performance:
+121.06%
1Y Performance:
+64.02%
1-Day Range:
$26.00
$27.90
1-Week Range:
$24.68
$28.74
52-Week Range:
$4.8069
$28.74
Mbx Biosciences Inc Stock (MBX) Company Profile
Name
Mbx Biosciences Inc
Sector
Industry
Phone
(317) 989-3100
Address
11711 N. MERIDIAN STREET, CARMEL
Compare MBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
27.08 | 1.21B | 0 | -47.20M | -43.65M | -1.5653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-25 | Initiated | TD Cowen | Buy |
| Oct-15-25 | Initiated | Truist | Buy |
| Aug-15-25 | Resumed | Jefferies | Buy |
| Aug-05-25 | Initiated | Mizuho | Outperform |
| Jul-16-25 | Initiated | Oppenheimer | Outperform |
| Apr-10-25 | Initiated | Citizens JMP | Mkt Outperform |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | JP Morgan | Overweight |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Stifel | Buy |
View All
Mbx Biosciences Inc Stock (MBX) Latest News
Will MBX Biosciences Inc. stock outperform tech sector in 2025Earnings Miss & Low Risk High Reward Ideas - newser.com
Is MBX Biosciences Inc. stock a safe buy before earningsSell Signal & Precise Swing Trade Entry Alerts - newser.com
Will MBX Biosciences Inc. stock rally after Fed decisionsTrade Risk Report & AI Enhanced Trade Execution Alerts - newser.com
MBX Biosciences, Inc. (NASDAQ:MBX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
MBX Biosciences stock maintains Buy rating at Jefferies on strong Phase 2 data - Investing.com Nigeria
Can MBX Biosciences Inc. stock resist sector downturns - newser.com
Will MBX Biosciences Inc. stock remain a Wall Street favorite2025 Technical Patterns & Risk Controlled Daily Trade Plans - newser.com
MBX: Strong clinical progress and funding position drive multiple catalysts in endocrine and metabolic pipeline - TradingView
MBX: Strong clinical progress and funding drive late-stage catalysts in endocrine and metabolic programs - TradingView
How rising interest rates impact MBX Biosciences Inc. stockQuarterly Performance Summary & Precise Entry and Exit Recommendations - newser.com
Chart based exit strategy for MBX Biosciences Inc.Recession Risk & Smart Swing Trading Techniques - newser.com
Visualizing MBX Biosciences Inc. stock with heatmapsQuarterly Growth Report & Consistent Profit Trading Strategies - newser.com
What machine learning models say about MBX Biosciences Inc.Earnings Trend Report & Growth Focused Stock Reports - newser.com
Using flow based indicators on MBX Biosciences Inc.July 2025 Retail & Risk Controlled Stock Pick Alerts - newser.com
Will MBX Biosciences Inc. stock go up soon2025 Analyst Calls & Reliable Volume Spike Alerts - newser.com
Detecting price anomalies in MBX Biosciences Inc. with AIFed Meeting & High Accuracy Swing Entry Alerts - newser.com
Does MBX Biosciences Inc. fit your quant trading modelJuly 2025 Retail & Fast Entry High Yield Tips - newser.com
MBX Biosciences Advances Phase 2a Study on PBH Treatment with Imapextide - MSN
MBX Biosciences (NASDAQ:MBX) Reaches New 12-Month HighStill a Buy? - MarketBeat
MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference - The Manila Times
MBX Biosciences (Nasdaq: MBX) joins 37th Piper Sandler Healthcare Conference webcast - Stock Titan
Why Is MBX Biosciences, Inc. Common Stock (MBX) Stock Up Today? - Meyka
What indicators show strength in MBX Biosciences Inc.July 2025 Closing Moves & Verified Momentum Stock Ideas - newser.com
Mbx Biosciences stock hits 52-week high at 26.5 USD By Investing.com - Investing.com Nigeria
Sentiment analysis tools applied to MBX Biosciences Inc.July 2025 Catalysts & Safe Entry Momentum Stock Tips - newser.com
Mbx Biosciences Inc Stock (MBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):